Across TCGA pan-cancer cohorts, MIR517B RNA is linked to patient survival in 4 of 34 cancer types, making it the most broadly survival-associated MIR517B data layer compared with 2 for mutation status.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR517B RNA is associated with better overall survival. In most high-consensus cancer types, elevated MIR517B expression acts as an unfavorable survival marker, although some lineages such as STAD and ESCA show a favorable association.

STAD, TGCT, and LGG are the cancer types where MIR517B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	IV	1.000	0.277	.023	36	view →
TGCT	OS	Tertile	All	0.836	0.991	.017	36	view →
LGG	DFS	Tertile	All	0.110	0.826	<.001	18	view →
ESCA	OS	Tertile	III,IV	1.000	0.375	.044	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MIR517B tumor-vs-normal RNA expression · all MIR517B data types